Germline genome editing alters DNA in eggs, sperm, or early embryos so changes are heritable. This raises distinct questions about safety, consent, and justice because effects extend beyond the individual to descendants and populations. Jennifer Doudna, University of California, Berkeley, has publicly urged a cautious path that prioritizes robust evidence and broad societal deliberation. The episode involving He Jiankui, Southern University of Science and Technology, who announced the birth of gene-edited children without transparent oversight, illustrates the practical and moral risks that can arise when governance and ethical norms are weak.
Ethical arguments in favor
Proponents emphasize the potential to prevent serious heritable diseases and to reduce suffering across generations. The National Academies of Sciences, Engineering, and Medicine has evaluated the scientific and ethical dimensions and emphasized that under stringent conditions, clinical applications might eventually be considered when risks are well understood and societal consensus supports them. The United Kingdom’s Human Fertilisation and Embryology Authority has permitted mitochondrial replacement techniques to prevent mitochondrial disease, creating a regulatory precedent in which certain heritable interventions are judged acceptable within a controlled framework. Advocates also invoke the ethical principle of beneficence, arguing that avoiding preventable disease can be a moral good when interventions are safe, effective, and equitably available.
Ethical arguments against
Opponents highlight unresolved risks such as unintended genetic changes, mosaicism, and complex gene–environment interactions that could produce harmful outcomes for future persons who cannot consent. There are profound concerns about justice because access to cutting-edge technologies often follows wealth and power, potentially exacerbating social inequalities. Critics also warn of slippery slopes toward non-therapeutic enhancement and forms of eugenics that devalue diversity and marginalize already vulnerable groups. Cultural and religious perspectives vary widely; some communities view altering lineage as morally impermissible, and indigenous and minority groups can be especially skeptical given historical abuses in medical research. These human and cultural nuances complicate any universal ethical claim.
Governance and consequences
Responsible policy requires transparent, multidisciplinary oversight, international coordination, and meaningful public engagement. The World Health Organization has called for global governance mechanisms and registries to track research and clinical uses, stressing that ad hoc national responses are insufficient when heritable changes cross borders. Consequences of premature or poorly regulated use include loss of public trust in science, reproductive tourism that exploits regulatory gaps, ecological unknowns if edited traits affect population dynamics, and geopolitical tensions over differing national policies. At present, many expert bodies conclude that routine clinical germline editing is not ethically acceptable until safety, efficacy, equitable access, and governance are demonstrably in place.
Ethical acceptability therefore depends on meeting high thresholds for scientific validity, informed collective consent, and fair distribution of benefits, accompanied by durable international oversight. Without those safeguards, the moral and social costs outweigh potential benefits.